Menu

 

 
Task Last Updated: 12/12/2006 
Division Name: Human Research 
Program/Discipline: NSBRI Teams 
Element/Subdiscipline: Smart Medical Systems Team 
Project Title: Contrast Agents for High-Intensity Focused Ultrasound Hemostasis 
Joint Agency Name:  
PI Name: Zderic, Vesna   PI Phone: 206-818-0960  
PI Email: zderic@gwu.edu  Fax:  
PI Organization Type: UNIVERSITY 
Organization Name: University of Washington 
PI Address 1: 1705 NE Pacific Street 
PI Address 2:  
PI Web Page:  
City: Seattle State: WA Zip Code: 98195 Congressional District: 7
Comments:  
Project Type: GROUND  Solicitation: NSBRI-RFP-04-01 
Start Date: 11/01/2004  End Date: 10/31/2006 
Fiscal Year: 2005     
No. of Post Docs:   No. of PhD Degrees:  
No. of PhD Candidates:   No. of Master' Degrees:  
No. of Master's Candidates:   No. of Bachelor's Degrees:  
No. of Bachelor's Candidates:   Monitoring Center: NSBRI 
Contact Monitor:   Contact Phone:  
Contact Email:      
Flight Program:  
Flight Assignment:

 
Key Personnel Changes/Previous PI:  
COI Name: COI Institution:
Crum, Lawrence   University of Washington 
Grant/Contract No.: NCC 9-58-PF00505 
Performance Goal No.:  
Performance Goal Text:

 
Task Description:  POSTDOCTORAL FELLOWSHIP

(1) Original aims. The hypothesis is that the application of ultrasound contrast agents will improve efficacy of HIFU hemostasis of injured solid organs, while maintaining the treatment safety.

Specific Aim 1: Determination of efficacy and safety of HIFU hemostasis in the presence of ultrasound contrast agents. Aim 1a: Mechanisms of HIFU hemostasis in the presence of commercially available UCA Optison. Thermal, mechanical and biological mechanisms of hemostasis in the presence of Optison will be investigated for the treatment optimization. Aim 1b: Efficacy and safety of HIFU hemostasis in the presence of Optison. Hemostasis efficacy will be determined, as well as healing of hemostatic liver incisions in rabbits for up to 60 days after the treatment.

Specific Aim 2: Development and testing of autologous UCA for HIFU hemostasis. Aim 2a: Development of autologous UCA. UCA consisting of blood, saline and air will be produced, characterized, and optimized for hemostasis application. Aim 2b: Determination of the efficacy of HIFU hemostasis in the presence of autologous UCA. HIFU treatment of liver incisions will be performed in the presence of autologous UCA to determine the treatment efficacy in producing hemostasis.

 
Research Impact/Earth Benefits: On Earth, bleeding due to blunt trauma is one of the primary causes of death within an hour after the injury if adequate care is not provided (Sauaia et al. 1995, Franklin et al. 2000). Rapid achievement of hemostasis is necessary to prevent hemorrhagic shock following intra-abdominal injury (Feliciano et al. 2000). However, hemostasis is not an easy task in trauma patients, due to the usual presence of coagulopathy, resulting from hypothermia, acidosis, and dilution of clotting factors (Bellamy 1984). The difficulties associated with treating battlefield and civilian trauma hemorrhage are in being able to detect and localize the hemorrhage site, and to stop the bleeding non-invasively, all within a very short time (of several minutes) after the trauma has occurred. Our group has demonstrated a potential of ultrasound-guided HIFU to both detect a bleeding site and deliver energy to produce hemostasis. Our current NSBRI-funded project addresses the HIFU hemorrhage control from solid organs in the presence of ultrasound contrast agents (UCA). The administration of UCA may facilitate detection and localization of bleeding sites, and allow faster hemorrhage control. Our eventual goal is to develop a portable automatic HIFU device that can be used at the site of accident to localize and stop the bleeding by a non-skilled operator, similar to current usage of defibrillators.

Task Progress: New project for FY2005; no progress this reporting period.

 
Bibliography Type: Description: (Last Updated: 04/10/2008)